Microcarriers in Cell Culture Market Size, Share & Industry Analysis, By Material (Synthetic Polymer, Natural Polymer, and Others), By Cell Type (Stem Cells, Primary & Differentiated Cells, and Others), By Application (Vaccine & Viral Vector Production, Biopharmaceutical & Recombinant Protein Production, Cell Therapy & Regenerative Medicine, Tissue Engineering, and Others), By End User (Pharmaceutical & Biotechnology Companies, Contract Manufacturing & Research Organizations, and Others), and Regional Forecast, 2026-2034

The global microcarriers in cell culture market size was valued at USD 690.0 million in 2025 and is projected to reach USD 1,630.0 million by 2034, exhibiting a CAGR of 10.2% during the forecast period.

The market is expected to grow significantly during the forecast period with the rising prevalence of chronic, genetic, and autoimmune diseases and demand for monoclonal antibodies, vaccines, and cell-based therapies. Microcarriers are the spherical beads used extensively in cell culture applications to facilitate the growth of cells. These carriers provide a large surface area within a bioreactor, enabling high-density cell culture in suspension. This is essential for large-scale production of biopharmaceuticals, vaccines, and regenerative medicine products.

Additionally, the rising prevalence of diseases, investments, and government initiatives to develop personalized medicine further boost market expansion.

• For instance, in January 2024, AbbVie Inc. collaborated with Umoja Biopharma to develop multiple in-situ generated, CAR T cell therapy candidates in oncology using the company's VivoVecTM platform. Such developments aimed to boost the adoption of products and propel market growth.

Microcarriers in Cell Culture Market Driver

Surging Demand for Cell-Based Therapies to Drive Market Growth

The increasing demand for cell-based therapies is a key driver contributing to the market growth. These innovative treatments offer promising solutions for various chronic and degenerative diseases. With advancements in regenerative medicine, the understanding of cellular mechanisms has expanded the therapeutic potential of cell-based approaches. Thus, the escalating adoption of these microcarriers for the development of cell-based therapies to accelerate market growth significantly.

• For instance, in October 2023, Bayer AG established its first Cell Therapy Facility in Berkeley, California, to bring cell therapies to patients on a global scale. Further, this facility aimed to supply the material required for late-stage clinical trials and the launch of BlueRock Therapeutics’ bemdaneprocel (BRT-DA01), a cell therapy for treating Parkinson’s disease.

Download Free sample to learn more about this report.

According to the American Lung Association, in 2019, 221,097.0 people were diagnosed with lung cancer in the U.S., which increased to 238,000.0 in 2023.

Microcarriers in Cell Culture Market Restraints

High Cost of Manufacturing to Hamper the Market Growth

High manufacturing costs associated with microcarriers are a significant barrier to their widespread adoption. For the production of these microcarriers, sophisticated technology, high-quality raw materials, and precise manufacturing processes are required, which elevates the prices. These factors are likely to limit their adoption in small to mid-sized companies, restricting the market growth.

Microcarriers in Cell Culture Market Opportunity

Development of Advanced Material for Microcarriers to Offer Lucrative Growth Opportunities

The rising research and development and material technologies for cost-effective and scalable outcomes in the development of therapies and vaccines are expected to propel the market during the forecast period. Additionally, key players in the market are focusing on the development and launch of advanced nanofibre-based microcarriers to boost the adoption and demand.

• For instance, in October 2025, Cellevate unveiled its new Cellevat3d VAX nanofiber microcarriers. This new nanofiber microcarriers is a technology that improves the scalability and cost-efficiency of adherent cell-based viral vaccine production.

Segmentation

Key Insights

The report covers the following key insights:

• Epidemiology of Key Diseases, By Key Countries/ Regions, 2025
• Key Industry Developments (Mergers, Acquisitions, Collaborations, and Others)
• Regulatory Scenario, By Key Countries/ Regions
• Overview: Usage of Microcarriers in Cell Culture
• Technological Advancements in the Market

Analysis by Material

Based on material, the market is subdivided into synthetic polymer, natural polymer, and others.

The synthetic polymer dominated the market. Olezarsen's efficacy in lowering triglycerides fosters the dominant share of the segment. Additionally, studies are underway to demonstrate its effectiveness in boosting demand for the product in the market.

• For instance, in November 2025, Kuraray Co., Ltd. launched SCAPOVA AS, a new variation in the SCAPOVA PVA microcarrier series in Japan. It is an uncoated microcarrier-treated PVA hydrogel surface used for cell culture applications.

Analysis by Cell Type

The market, in terms of cell type, has been studied across stem cells, primary & differentiated cells, and others.

The stem cells segment is expected to grow significantly during the forecast period. The segment’s growth is augmented by the increasing prevalence and demand for stem cell-based products.

• For instance, in July 2024, Bioserve India launched advanced stem cell products for REPROCELL in India.

Analysis by Application

On the basis of segmentation by application, the market is categorized into vaccine & viral vector production, biopharmaceutical & recombinant protein production, cell therapy & regenerative medicine, tissue engineering, and others.

The vaccine & viral vector production segment is expected to experience exponential growth during the forecast period. The increasing production of vaccines for preventive medication is slated to boost the adoption of cell culture microcarriers and product demand.

• For example, in June 2021, Merck & Co., Inc., in collaboration with Sanofi, announced the commercialization of VAXELIS (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine).

Analysis by End User

Based on end user, the market is fragmented into pharmaceutical & biotechnology companies, contract manufacturing & research organizations, and others.

The pharmaceutical & biotechnology companies segment held the largest market share. The presence of advanced research facilities and investments for the development of cell therapy and regenerative medicines are likely to boost the segment’s growth.

• For instance, in March 2023, Dai Nippon Printing Co., Ltd. (DNP) and Hyperion Drug Discovery Co., Ltd. (HDD) developed soluble microcarriers used as scaffolding agents in cell culture processes, for cell and gene-based products, exosomes, biopharmaceuticals, and cultured meat.

Regional Analysis

Request for Customization   to gain extensive market insights.

The market, in terms of region, has been studied across Asia Pacific, Latin America, North America, Europe, and the Middle East & Africa.

North America accounted for a dominant share of the global microcarriers in cell culture market in 2025. The rising prevalence of chronic diseases and the availability of advanced research and development facilities are expected to drive the market's growth in the region. A strong presence of key players, along with extended clinical studies, is expected to boost the market's growth.

• For instance, in November 2024, Ro IamFluidics B.V. launched a dissolvable microcarrier for adherent cell culturing to be used for advanced cell therapies and biologics manufacturing.

Europe holds a considerable market share. Increasing focus toward biopharmaceutical research and manufacturing, and the launch of cell therapies, are expected to drive the region's market growth.

• For instance, in November 2025, U.K.-developed cell therapy Aucatzyl (obecabtagene autoleucel) was approved by England’s National Health Service (NHS) for treating relapsed or refractory B-cell acute lymphoblastic leukaemia (ALL).

Moreover, the Asia Pacific is expected to grow at a significant CAGR during the forecast period. The increasing prevalence of chronic diseases and the presence of key players in the market with advanced product offerings for research and development in the region are expected to propel the segment’s growth.

Key Players Covered

The global microcarriers in cell culture market is highly fragmented, with a large number of smaller providers.

The report includes the profiles of the following key players:

• Cytiva (U.S.)
• Sartorius (Germany)
• Corning Life Sciences (U.S.)
• Merck KGAa (Germany)
• Thermo Fisher Scientific (U.S.)
• Percell Biolytica (Sweden)
• Global Cell Solutions (U.S.)
• Holves (China)
• Bestchrom (China)
• Nexture Bio (U.S.)

Key Industry Developments

• May 2025: Nexture Bio launched a robust suite of custom research and development services to support customers in optimizing cell culture on ACF microcarriers and scaffolds for scaling adherent cell culture bioprocesses.
• October 2023: Thermo Fisher Scientific launched the Gibco CTS Detachable Dynabeads platform to enhance cell therapy manufacturing.